Mirati Therapeutics reported a Q2 2023 net loss per share of USD 3.04, beating estimates by 4.1% YoY. The biopharma's net loss rose 0.3% YoY to USD 176.9 million. Net product revenue was USD 13.4 million from the newly launched KRAZATI.
Operating expenses increased 10.1% YoY, driven by a 39.3% YoY rise in selling/admin costs from expanded headcount and KRAZATI commercialization. This was partially offset by a 3.2% YoY R&D spending decrease due to reduced sitravatinib clinical costs and lower share-based compensation.
Mirati announced an underwritten public offering of 9.7 million shares plus 1.1 million warrant shares, aiming to raise approximately USD 300 million. Net proceeds will fund drug development and leadership expansion and is expected to close on August 12, 2023.
The cash, cash equivalents, and short-term investments for June 2023 stood at USD 779.4 million compared to USD 1.1 billion at the end of Q4 2022. The company did not provide guidance for 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.